[ 18 F]FE‐PE2I PET is a diagnostic tool in dementia with Lewy bodies

Le résumé fourni par la source

Abstract Aim Dementia with Lewy bodies (DLB) is characterized by motor and non‐motor symptoms. The degeneration of the dopaminergic pathway is a hallmark of DLB; for this reason, we aimed to study a recent dopamine transporter (DAT) positron emission tomography (PET) radioligand as a diagnostic tool for DLB. Methods In this study, we used DAT–PET with the radioligand [ 18 F]FE‐PE2I to distinguish DLB subjects from healthy controls (HCs). We also aimed to analyze how DAT binding correlated with clinical features, amyloid load, measured by PET, and cardiac metaiodobenzylguanidine scintigraphy (MIBG). Results Binding potential ( BP ND ) values of [ 18 F]FE‐PE2I were higher in HCs versus DLB in striatum (1.82 ± 0.34 vs. 1.15 ± 0.34; p < 0.001; 95% Confidence Interval [CI]: 0.40–0.96), putamen (2.2 ± 0.36 vs. 1.41 ± 0.51; p < 0.001; 95% CI: 0.39–1.17), caudate (1.38 ± 0.30 vs. 0.88 ± 0.20; p < 0.001; 95% CI: 0.28–0.70), and substantia nigra (0.49 ± 0.091 vs. 0.42 ± 0.084; p = 0.0437; 95% CI: 0.003 to 0.14). After adjusting for age, substantia nigra did not differ between DLB and HCs ( p : 0.46; 95% CI: −0.049 to 0.11); however, BP ND values between DLB and HC in striatum ( p : <0.001; 95% CI: 0.25–0.85), putamen ( p : 0.0012; 95% CI: 0.31–1.13), and caudate ( p : 0.0027; 95% CI: 0.13–0.55) were still significant. Striatum was the best area to correctly classify DLB subjects versus HC compared to the putamen, caudate, and substantia nigra (area under the curve = 0.95, 0.90, 0.93, and 0.73, respectively; 95 CI: 0.87–1.00, 0.79–1.00, 0.84–1.00, 0.55–0.92, respectively). Subjects with altered MIBG showed lower BP ND compared to subjects with normal MIBG in the putamen. Conclusion Our study showed that [ 18 F]FE‐PE2I PET represents a potential diagnostic tool with high accuracy in discriminating DLB patients versus HC, which is valuable for clinical practice.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.